Processa Pharmaceuticals Amends 10-K to Detail $1.4M Capital Raises and Executive Compensation

summarizeSummary

Processa Pharmaceuticals filed an amended annual report (10-K/A) to include previously omitted information regarding executive compensation, beneficial ownership, and significant capital raises totaling $1.4 million from The Chiliz Group.

check_boxKey Events

• Details $1.4 Million in Capital Raises

  The amendment discloses that the company sold 218,688 shares for $1.2 million in net proceeds to The Chiliz Group on August 4, 2025, and an additional 86,956 shares for $200,000 on February 17, 2026. These transactions provide significant funding for the company.

• Executive Officer Transition

  Dr. Sian Bigora, Chief Development and Regulatory Officer, will transition from a full-time executive role to a part-time employee position effective May 1, 2026, and will no longer be designated an executive officer.

• Comprehensive Compensation Disclosure

  The filing includes detailed executive and director compensation for the fiscal year ended December 31, 2025, outlining salaries, bonuses, and equity awards for key personnel.

• Updated Beneficial Ownership Information

  The report provides updated beneficial ownership data as of April 29, 2026, identifying The Chiliz Group as an 11.2% owner and Mitchell Kopin, Daniel Asher, and Intracoastal Capital, LLC as 7.3% owners. Officers and directors collectively own 2.8%.

auto_awesomeAnalysis

This 10-K/A filing provides crucial missing information from the original annual report, offering investors a more complete financial and operational picture. The disclosure of $1.4 million in capital raises from The Chiliz Group, while historical, is significant for a company of this size, providing insight into its funding strategy and potential dilution. The detailed executive and director compensation, along with beneficial ownership information, enhances transparency. The transition of a key executive to a part-time role is a minor organizational change. Overall, this amendment addresses compliance gaps and offers important retrospective financial context.